TABLE 1.
Plasma cohort patient characteristics
| Parameter | Cohort (n=99) | PHLF cohort (n=24) | No PHLF cohort (n=75) | Missing values (%) |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 65 (65.7) | 13 (54.2) | 52 (69.3) | |
| Female | 34 (34.3) | 11 (45.8) | 23 (30.7) | |
| Age (y) | 62.5 (22.0–86.0) | 62.4 (35.0–80.7) | 62.6 (22.0–86.0) | |
| Hepatic resection, n (%) | ||||
| Minor (<3 segments) | 26 (26.3) | 2 (8.3) | 24 (32.0) | |
| Major (≥ 3 segments) | 73 (73.7) | 22 (91.7) | 51 (68.0) | |
| Tumor type, n (%) | ||||
| mCRC | 34 (34.3) | 4 (16.7) | 30 (40.0) | |
| HCC | 29 (29.3) | 5 (20.8) | 24 (32.0) | |
| CCC | 21 (21.2) | 10 (41.7) | 11 (14.6) | |
| Pancreas related | 8 (8.1) | 3 (12.5) | 5 (6.7) | |
| Others | 7 (7.1) | 2 (8.3) | 5 (6.7) | |
| Hepatic comorbidities | ||||
| Neoadjuvant CTx, n (%) | 34 (35.7) | 5 (21.7) | 19 (26.4) | 4 (4.0) |
| Steatosis (%) | 14.0 (0.0–100.0) | 6.8 (0.0–40.0) | 17 (0.0–100.0) | |
| Steatohepatitis, n (%) | 25 (26.0) | 4 (18.2) | 21 (28.4) | 3 (3.0) |
| Fibrosis, n (%) | 55 (57.3) | 11 (52.4) | 44 (58.7) | 3 (3.0) |
| CASH, n (%) | 19 (19.6) | 3 (13.6) | 16 (21.3) | 2 (2.0 |
| Intraoperative RBCs transfusion, n (%) | 10 (10.1) | 4 (16.7 | 6 (8.0) | |
| Hepatitis, n (%) | 8 (8.1) | 1 (4.2) | 7 (9.3) | |
| Antivirals, n (%) | 3 (3.0) | 0 (0.0) | 3 (4.0) | |
| Preoperative parameters | ||||
| PDR (%) | 20.9 (9.0–40.0) | 21.3 (9.7–40.0) | 20.8 (9.0–38.3) | 24 (24.2) |
| Platelets (×103/µL) | 248.7 (86.0–487.0) | 262.4 (172.0–345.0) | 237 (86.0–487.0) | 10 (10.1) |
| SB (mg/dL) | 0.8 (0.2–6.6) | 1.0 (0.2–6.6) | 0.7 (0.2–6.6) | 13 (13.1) |
| PT (%) | 104.6 (40.0–150.0) | 97.2 (40.0–150.0) | 107.0 (74.0–150.0) | 18 (18.2) |
| AP (U/L) | 129.7 (46.0–707.0) | 162.8 (51.0–707.0) | 100.0 (46.0–314.0) | 16 (16.2) |
| GGT (U/L) | 147.2 (7.0–1576.0) | 211.3 (18.0–1576) | 127 (7.0–710.0) | 11 (11.1) |
| AST (U/L) | 45.4 (14.0–242.0) | 53.9 (14.0–224.0) | 44.0 (17.0–242.0) | 28 (28.3) |
| ALT (U/L) | 45.97 (8.0–372.0) | 44.2 (12.0–129.0) | 48.0 (8.0–372.0) | 11 (11.1) |
| Albumin (g/L) | 41.4 (32.5–47.6) | 38.8 (32.5–47.3) | 43.2 (34.4–47.6) | 19 (19.2) |
| Morbidity, n (%) | ||||
| No morbidity | 46 (46.5) | 4 (16.7) | 42 (56.0) | |
| Grade I | 12 (12.1) | 2 (8.3) | 10 (13.3) | |
| Grade II | 19 (19.2) | 7 (29.2) | 12 (16.0) | |
| Grade III | 16 (16.2) | 6 (25.0) | 10 (13.3) | |
| Grade IV | 2 (2.0) | 2 (8.3) | 0 (0.0) | |
| Grade V | 4 (4.0) | 3 (12.5) | 1 (1.4) | |
| Postoperative stay | ||||
| ICU (d) | 2.1 (0.0–15.0) | 2.9 (0.0–15.0) | 2 (0.0–15.0) | |
| Total hospitalization (d) | 13.6 (4.0–75.0) | 19.5 (5.0–56.0) | 12.0 (4.0–75.0) | |
| PHLF ISGLS, n (%) | ||||
| No PHLF | 75 (75.7) | 75 (100.0) | ||
| Grade A | 6 (6.1) | 6 (25.0) | ||
| Grade B | 7 (7.1) | 7 (29.2) | ||
| Grade C | 11 (11.1) | 11 (45.8) | ||
Note: Values in bold: PHLF vs. noPHLF: p>0.05.
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; CCC, cholangiocellular carcinoma; CASH, chemotherapy-induced acute steatohepatitis; CTx, chemotherapy; GGT, gamma-glutamyl transpeptidase; ICU, intensive care unit; ISGLS, International Study Group of Liver Surgery; mCRC, metastatic colorectal cancer; PDR, plasma disappearance rate; PHLF, posthepatectomy liver failure; PT, prothrombin time; RBCs, red blood cells; SB, serum bilirubin.